First Tracks Biotherapeutics, Inc. (TRAX)
39.04
+0.57
(+1.48%)
USD |
NASDAQ |
Sep 16, 16:00
39.04
0.00 (0.00%)
After-Hours: 19:18
First Tracks Biotherapeutics Enterprise Value : 1.198B for Sept. 15, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 15, 2026 | 1.198B |
| September 14, 2026 | 1.166B |
| September 11, 2026 | 1.126B |
| September 10, 2026 | 1.180B |
| September 09, 2026 | 1.237B |
| September 08, 2026 | 1.316B |
| September 04, 2026 | 1.268B |
| September 03, 2026 | 1.341B |
| September 02, 2026 | 1.439B |
| September 01, 2026 | 1.293B |
| August 31, 2026 | 1.317B |
| August 28, 2026 | 1.318B |
| August 27, 2026 | 1.420B |
| August 26, 2026 | 1.400B |
| August 25, 2026 | 1.433B |
| August 24, 2026 | 1.368B |
| August 21, 2026 | 1.362B |
| August 20, 2026 | 1.319B |
| August 19, 2026 | 1.447B |
| August 18, 2026 | 1.389B |
| August 17, 2026 | 1.379B |
| August 14, 2026 | 1.395B |
| August 13, 2026 | 1.395B |
| August 12, 2026 | 1.469B |
| August 11, 2026 | 1.491B |
| Date | Value |
|---|---|
| August 10, 2026 | 1.532B |
| August 07, 2026 | 1.441B |
| August 06, 2026 | 1.440B |
| August 05, 2026 | 1.498B |
| August 04, 2026 | 1.465B |
| August 03, 2026 | 1.470B |
| July 31, 2026 | 1.395B |
| July 30, 2026 | 1.527B |
| July 29, 2026 | 1.318B |
| July 28, 2026 | 1.317B |
| July 27, 2026 | 1.324B |
| July 24, 2026 | 1.093B |
| July 23, 2026 | 1.168B |
| July 22, 2026 | 1.187B |
| July 21, 2026 | 1.159B |
| July 20, 2026 | 1.141B |
| July 17, 2026 | 1.129B |
| July 16, 2026 | 1.118B |
| July 15, 2026 | 1.115B |
| July 14, 2026 | 1.053B |
| July 13, 2026 | 1.075B |
| July 10, 2026 | 1.119B |
| July 09, 2026 | 982.97M |
| July 08, 2026 | 571.38M |
| July 07, 2026 | 536.34M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Forte Biosciences, Inc. | 1.378B |
| Immunovant, Inc. | 6.762B |
| ACADIA Pharmaceuticals, Inc. | 3.724B |
| Agenus, Inc. | 569.79M |
| Alnylam Pharmaceuticals, Inc. | 31.54B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -33.37M |
| Total Expenses (Quarterly) | 33.37M |
| EPS Diluted (Quarterly) | -0.943 |
| Earnings Yield | -12.66% |
| Normalized Earnings Yield | -12.66 |